{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:24:05Z","timestamp":1759940645258},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/bf02716583","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T14:49:27Z","timestamp":1191336567000},"page":"377-388","source":"Crossref","is-referenced-by-count":1,"title":["F\u00e1rmacos antif\u00fangicos. Situaci\u00f3n actual y pautas para su administraci\u00f3n"],"prefix":"10.1007","volume":"7","author":[{"given":"Rodrigo Fern\u00e1ndez","family":"Alonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma. Esther Gonz\u00e1lez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn Fern\u00e1ndez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Cepeda Piorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"4","key":"BF02716583_CR1","first-page":"387","volume":"15","author":"JM Aguado","year":"2002","unstructured":"Aguado JM, Garc\u00eda Rodr\u00edguez JA, Gobernado M, et al. Profilaxis y tratamiento de las infecciones f\u00fangicas en el paciente oncohematol\u00f3gico. Rev Esp Quimioterap. 2002; 15(4):387\u2013401.","journal-title":"Rev Esp Quimioterap"},{"key":"BF02716583_CR2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/322606","volume":"33","author":"M McNeil","year":"2001","unstructured":"McNeil M, Nash SL, Hajjeh RT. Trends in mortality due to invasive myotic diseases in the United States, 1980\u20131997. Clin Infect Dis. 2001;33:641\u20137.","journal-title":"Clin Infect Dis"},{"key":"BF02716583_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/clinids\/22.Supplement_2.S89","volume":"22","author":"MA Pfaller","year":"2005","unstructured":"Pfaller MA. Nosocomial Candidiasis: emerging species. Reservoirs and modes of transmission. Clin Infect Dis. 1996;22:89\u201394.","journal-title":"Clin Infect Dis"},{"key":"BF02716583_CR4","first-page":"117","volume":"8","author":"C Verfaille","year":"1991","unstructured":"Verfaille C, Wisdorf R, Haake R, Hostetter M, Ramsey N, Mc Glave P. Candida infections in bone morrow transplant recipients. Bone Morrow Transplant. 1991;8:117\u201384.","journal-title":"Bone Morrow Transplant"},{"key":"BF02716583_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03259.x","volume":"116","author":"R Martina","year":"2001","unstructured":"Martina R, Subir\u00e1 M, Rovira M. Invasive fungal infections after allogenic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol. 2001;116:475\u201382.","journal-title":"Br J Haematol"},{"key":"BF02716583_CR6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","volume":"37","author":"D Derring","year":"1998","unstructured":"Derring D, Marinus A, Cohen J. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients. Diagnosis and therapeutic outcome EORTC Invasive Fungal Infections Cooperative group. J Infect. 1998;37:173\u201380.","journal-title":"J Infect"},{"key":"BF02716583_CR7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","volume":"175","author":"A Wald","year":"1997","unstructured":"Wald A, Leisenring W, Van Burik J, Bowden R. Epidemiology infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175:1459\u201366.","journal-title":"J Infect Dis"},{"key":"BF02716583_CR8","volume-title":"Las bases farmacol\u00f3gicas de la terap\u00e9utica. 8a. ed. en espa\u00f1ol","author":"A Goodman Gilman","year":"2005","unstructured":"Goodman Gilman A. Las bases farmacol\u00f3gicas de la terap\u00e9utica. 8a. ed. en espa\u00f1ol. M\u00e9xico: Mc Graw hill Interamericano: 1996."},{"key":"BF02716583_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","volume":"33","author":"AH Grol","year":"2005","unstructured":"Grol AH, Shah PM, Menzel C. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23\u201332.","journal-title":"J Infect"},{"key":"BF02716583_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0304-4157(86)90002-X","volume":"864","author":"J Boland","year":"1986","unstructured":"Boland J. How do the polyne macrolide antibiotics affect the celular membrane properties? Biochim Biophys Acta. 1986;864:257\u2013304.","journal-title":"Biochim Biophys Acta"},{"key":"BF02716583_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","volume":"12","author":"HA Gallis","year":"1990","unstructured":"Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308\u201329.","journal-title":"Rev Infect Dis"},{"key":"BF02716583_CR12","first-page":"263","volume":"39","author":"M Schafer-Korting","year":"2005","unstructured":"Schafer-Korting M, Blachschsmidt J, Korting HC. Clinical use of oral nysttin in the prevention of systemic candidosis in patients at particular risk. Mycoses. 1996;39:263\u201372.","journal-title":"Mycoses"},{"key":"BF02716583_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","volume":"32","author":"J Heykants","year":"1989","unstructured":"Heykants J, Van Peer A, Van de Velde V. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32:67\u201387.","journal-title":"Mycoses"},{"key":"BF02716583_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003495-200161001-00004","volume":"61","author":"M Boogaerts","year":"2001","unstructured":"Boogaerts M Maertens J. Clinical experience with itraconazole in systemic infections. Drugs. 2001;61:39\u201347.","journal-title":"Drugs"},{"key":"BF02716583_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","volume":"61","author":"K Beule De","year":"2001","unstructured":"De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61:27\u201337.","journal-title":"Drugs"},{"key":"BF02716583_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199243020-00010","volume":"43","author":"JA Balfour","year":"1992","unstructured":"Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43:259\u201384.","journal-title":"Drugs"},{"key":"BF02716583_CR17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2230.1989.tb00900.x","volume":"14","author":"NS Ryder","year":"1989","unstructured":"Ryder NS. The mechanism of action of Terbinafine. Clin Exp Dermatol. 1989;14:98\u2013100.","journal-title":"Clin Exp Dermatol"},{"key":"BF02716583_CR18","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/clind\/15.6.1003","volume":"15","author":"P Francis","year":"1992","unstructured":"Francis P, Wlash TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992;15:1000\u201318.","journal-title":"Clin Infect Dis"},{"key":"BF02716583_CR19","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.41.10.2238","volume":"41","author":"TL Wallace","year":"1998","unstructured":"Wallace TL, Paetznick V, Cossum PA, L\u00f3pez-Berenstein G, Rex JH, Anaissiet. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. 1998; 41:2238\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02716583_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","volume":"346","author":"TJ Walsh","year":"2002","unstructured":"Walsh TJ, Pappar P, Winston DJ. Voriconazole compared with liposomal amphotericin B for empirical antifungical therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225\u201334.","journal-title":"N Engl J Med"},{"key":"BF02716583_CR21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbercht","year":"2002","unstructured":"Herbercht R, Denning DW, Ratterson TF. Voriconazole versus amphotericin B for primary therapy of invaseve aspergillosis. N Engl J Med. 2002;347:408\u201315.","journal-title":"N Engl J Med"},{"key":"BF02716583_CR22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.5-2-120","volume":"5","author":"CC Chiou","year":"2000","unstructured":"Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invaseve fungal infections in patients with cancer. The Oncologist. 2000;5:120\u201335.","journal-title":"The Oncologist"},{"key":"BF02716583_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF01575126","volume":"16","author":"TJ Walsh","year":"1997","unstructured":"Walsh TJ, Giri N. Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis. 1997;16:93\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"BF02716583_CR24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.43.6.1401","volume":"43","author":"RK Li","year":"1999","unstructured":"Li RK, Rinaldi MG. Antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 1999;43:1401\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02716583_CR25","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"J Mora Duarte","year":"2002","unstructured":"Mora Duarte J, Betts R, Rotstein C. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020\u20139.","journal-title":"N Engl J Med"},{"key":"BF02716583_CR26","unstructured":"Walsh T, Sable C, dePauw B. Cols. Trial of Caspofungin us liposomal Amphotericin of patients with persistant febrile neutropenia. Abstract M-1761 presentado en el 43th Annual ICAAC, Chicago, Illinois, USA. September 2003."},{"key":"BF02716583_CR27","first-page":"5","volume":"2","author":"F Marco","year":"2003","unstructured":"Marco F, Mensa J. Antif\u00fangicos. Situaci\u00f3n actual y perspectivas futuras. Infecce, Immunol. 2003;2:5\u201313.","journal-title":"Infecce, Immunol"},{"key":"BF02716583_CR28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/CMR.8.4.515","volume":"8","author":"TG Mitchel","year":"1995","unstructured":"Mitchel TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515\u201348.","journal-title":"Clin Microbiol Rev"},{"key":"BF02716583_CR29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1099\/0022-1317-51-5-433","volume":"51","author":"B Sendid","year":"2002","unstructured":"Sendid B, Piorot JL, Tabouret M. Combined detection of mannanaemia and antimannanatibodies as a strategy for the diagnosis of systemic infection caused by patogenic Candida Species. J Med Microbiol. 2002;51:433\u201342.","journal-title":"J Med Microbiol"},{"key":"BF02716583_CR30","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/JCM.35.12.3284-3287.1997","volume":"35","author":"JC Garc\u00eda Ruiz","year":"1997","unstructured":"Garc\u00eda Ruiz JC, Avilla MC, Reg\u00fadez P, Quindos G, \u00c1lvarez A, Pont\u00f3n J. Detection of antibodies toCanadida albicans germ tubes for dianosis, and therapeutic monitoring of invasive candidiasis in patients with haematologic malignancies. J Clin Microbiol. 1997;35:3284\u20137.","journal-title":"J Clin Microbiol"},{"key":"BF02716583_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/49.suppl_1.11","volume":"49","author":"Stevens","year":"2002","unstructured":"Stevens. Diagnosis of fungal infections: current status; J Antimicrob Chemother. 2002;49:11\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"BF02716583_CR32","first-page":"387","volume":"15","author":"JM Aguado","year":"2002","unstructured":"Aguado JM, Garc\u00eda Rodr\u00edguez JA, Gobesnado M, Prensa J, Picazo J (Sociedad Espa\u00f1ola de Quimioterapia); de la C\u00e1mara R, Carreras E, Sanz MA (Asociaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia). Temas de consenso; Profilaxis y tratamiento de las infecciones f\u00fangicas en el paciente oncohematol\u00f3gico. Rev Esp Quimioterap. 2002; 15:387\u2013401.","journal-title":"Rev Esp Quimioterap"},{"key":"BF02716583_CR33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0213-005X(03)72995-4","volume":"21","author":"J Gabald\u00e1","year":"2003","unstructured":"Gabald\u00e1 J, Ruiz I. Recomendaciones para el tratamiento de la infecci\u00f3n f\u00fangica invasiva. Infecci\u00f3n f\u00fangica invasiva porCandida spp. Enferm Infecc Microbiol Clin. 2003;21:498\u2013508.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"BF02716583_CR34","first-page":"23","volume":"2","author":"JA Mart\u00ednez","year":"2003","unstructured":"Mart\u00ednez JA. Protocolos de tratamiento de las infecciones f\u00fangicas invasivas. Infecc e Immunol. 2003;2:23\u201331.","journal-title":"Infecc e Immunol"},{"key":"BF02716583_CR35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/infdis\/172.4.1035","volume":"172","author":"A Schaffner","year":"1995","unstructured":"Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use and health care care costs in patients undergoing, intensive chemotherapy for hematologic neoplasias. J Infect Dis. 1995;172:1035\u201341.","journal-title":"J Infect Dis"},{"key":"BF02716583_CR36","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","volume":"33","author":"A Villanueva","year":"2001","unstructured":"Villanueva A, Arathoon E, Berman R, Dinubile M, Sable C. A randomized double-blind study of caspofungin versus amphotericin for the treatment ofCandida esophagitis. Clin Infect Dis. 2001;33:1529\u201335.","journal-title":"Clin Infect Dis"},{"key":"BF02716583_CR37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","volume":"113","author":"A Villanueva","year":"2002","unstructured":"Villanueva A, Gotuzzo E, Arathoon E. A ramdomized double-blind study of caspofungin versus fluconazole for the treatment of esofhageal candidiasis. Am J Med. 2002: 113:294\u20139.","journal-title":"Am J Med"},{"key":"BF02716583_CR38","first-page":"2227","volume":"12","author":"P Hegener","year":"1998","unstructured":"Hegener P, Troke P, Fakenheuer G, Diebil V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patient with AIDS. AIDS. 1998;12:2227\u20138.","journal-title":"AIDS"},{"key":"BF02716583_CR39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0145-2126(99)00129-0","volume":"23","author":"S Sallah","year":"1999","unstructured":"Sallah S, Semelka RC, Sallah W, Vaihright JR, Philips DL. Amphotericin B lipid complex for the treatment of patients with acute leukemia an hepatosplenic candidiasis. Leuk Res. 1999;23:995\u20139.","journal-title":"Leuk Res"},{"key":"BF02716583_CR40","first-page":"2929","volume":"155","author":"MH Nguyen","year":"1995","unstructured":"Nguyen MH, Peacock J, Tanner D. Therapeutic aproaches in patients with candidemia. Arch Internn Med. 1995;155:2929\u201335.","journal-title":"Arch Internn Med"},{"key":"BF02716583_CR41","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"J Mora Duarte","year":"2002","unstructured":"Mora Duarte J, Betts R, Rotstein C, Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020\u20139.","journal-title":"N Engl J Med"},{"key":"BF02716583_CR42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/515033","volume":"27","author":"M Ellis","year":"1998","unstructured":"Ellis M, Spence D, de Pauw B. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998; 27:1408\u201312.","journal-title":"Clin Infect Dis"},{"key":"BF02716583_CR43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF01575127","volume":"16","author":"K Torfs","year":"1997","unstructured":"Torfs K. Economic aspects of treatment for fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis. 1997;16:8\u2013107.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"BF02716583_CR44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003495-200161001-00002","volume":"61","author":"JFGM Meis","year":"2001","unstructured":"Meis JFGM, Werweig PE. Current management of fungal infections. Drugs. 2001;61:13\u201325.","journal-title":"Drugs"},{"issue":"1","key":"BF02716583_CR45","first-page":"51","volume":"61","author":"R Gool Van","year":"2001","unstructured":"Van Gool R. Coste del tratamiento de las infecciones f\u00fangicas sist\u00e9micas. Drugs Supplement. 2001;61:(1):51\u20139.","journal-title":"Drugs Supplement"},{"key":"BF02716583_CR46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.thj.6200424","volume":"5","author":"C Corddonier","year":"2004","unstructured":"Corddonier C. Fangal infections: Current diagnosis and treatment. Hematol J. 2004;5:S59\u201362.","journal-title":"Hematol J"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"es","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02716583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02716583\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02716583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:16:03Z","timestamp":1587946563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02716583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["BF02716583"],"URL":"https:\/\/doi.org\/10.1007\/bf02716583","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}